BR112020006246A2 - Método para controle do peso de um sujeito em necessidade - Google Patents

Método para controle do peso de um sujeito em necessidade Download PDF

Info

Publication number
BR112020006246A2
BR112020006246A2 BR112020006246-4A BR112020006246A BR112020006246A2 BR 112020006246 A2 BR112020006246 A2 BR 112020006246A2 BR 112020006246 A BR112020006246 A BR 112020006246A BR 112020006246 A2 BR112020006246 A2 BR 112020006246A2
Authority
BR
Brazil
Prior art keywords
semagglutide
week
use according
fact
subject
Prior art date
Application number
BR112020006246-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Maria Kabisch
Thomas Hansen
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60083831&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112020006246(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Publication of BR112020006246A2 publication Critical patent/BR112020006246A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BR112020006246-4A 2017-10-12 2018-10-10 Método para controle do peso de um sujeito em necessidade BR112020006246A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17196254.1 2017-10-12
EP17196254 2017-10-12
PCT/EP2018/077654 WO2019072941A1 (en) 2017-10-12 2018-10-10 SEMAGLUTIDE IN MEDICAL THERAPY

Publications (1)

Publication Number Publication Date
BR112020006246A2 true BR112020006246A2 (pt) 2021-03-30

Family

ID=60083831

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020006246-4A BR112020006246A2 (pt) 2017-10-12 2018-10-10 Método para controle do peso de um sujeito em necessidade

Country Status (18)

Country Link
US (4) US12029779B2 (https=)
EP (1) EP3694538A1 (https=)
JP (2) JP7148605B2 (https=)
KR (1) KR20200069316A (https=)
CN (4) CN120241968A (https=)
AU (2) AU2018348929B2 (https=)
BR (1) BR112020006246A2 (https=)
CA (1) CA3078652A1 (https=)
CL (1) CL2020000812A1 (https=)
IL (3) IL322968A (https=)
MA (1) MA50358A (https=)
MX (3) MX2020003049A (https=)
MY (1) MY204827A (https=)
PH (1) PH12020550185A1 (https=)
SG (1) SG11202002841PA (https=)
TW (1) TWI842681B (https=)
WO (1) WO2019072941A1 (https=)
ZA (3) ZA202503387B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023238017A1 (en) * 2022-06-08 2023-12-14 Zydus Lifesciences Limited Reusable multi-dose, variable dose, single pen injector for type 2 diabetes and weight management

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7148605B2 (ja) * 2017-10-12 2022-10-05 ノヴォ ノルディスク アー／エス 医学療法におけるセマグルチド
EP4104820A4 (en) 2020-02-14 2024-04-17 G2GBIO, Inc. Pharmaceutical composition comprising sustained-release microspheres including glp-1 analogue or pharmaceutically acceptable salt thereof
PE20230819A1 (es) 2020-02-18 2023-05-19 Novo Nordisk As Composiciones y usos de glp-1
US11478533B2 (en) * 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
EP4313016A4 (en) * 2021-03-29 2025-01-22 Sanford Health METHODS AND COMPOSITIONS FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES
WO2024249659A2 (en) * 2023-05-30 2024-12-05 The Medical College Of Wisconsin, Inc. Methods for weight loss and/or reducing weight gain
US12597496B2 (en) * 2023-06-05 2026-04-07 Closed Loop Medicine Ltd. Dosing of incretin pathway drugs

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
AU2002316811A1 (en) 2001-06-28 2003-03-03 Novo Nordisk A/S Stable formulation of modified glp-1
KR101241862B1 (ko) 2003-09-19 2013-03-13 노보 노르디스크 에이/에스 신규 ｇｌｐ-1 유도체
TR201906789T4 (tr) 2003-11-20 2019-05-21 Novo Nordisk As Üretim ve enjeksiyon cihazlarında kullanım için en uygun olan propilen glikol ihtiva eden peptit formülasyonları.
RU2413530C9 (ru) 2004-11-12 2021-05-18 Ново Нордиск А/С Стабильные препараты инсулинотропных пептидов
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
MX373000B (es) 2005-09-14 2020-05-21 Mannkind Corp Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
MX2008013216A (es) 2006-04-14 2008-10-27 Mannkind Corp Formulaciones farmaceuticas de peptido-1 tipo glucagon (glp-1).
EP2481410B1 (en) 2007-01-31 2016-07-13 BIAL - Portela & Ca., S.A. Nitrocatechol derivates as COMT inhibitors administered with a specific dosage regime
WO2008116088A1 (en) 2007-03-20 2008-09-25 Nippon Kayaku Kabushiki Kaisha Method to monitor drug efficacy in diabetic patients using an assay for 1,5-anhydro-d-glucitol
WO2009030774A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Truncated glp-1 derivatives and their therapeutical use
US8748377B2 (en) 2008-12-10 2014-06-10 Glaxosmithkline Llc Pharmaceutical compositions
EP2395988A2 (en) 2009-02-13 2011-12-21 Boehringer Ingelheim International GmbH Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
EP2512518A1 (en) 2009-12-16 2012-10-24 Novo Nordisk A/S Glp-1 receptor agonist compounds with a modified n-terminus
CA3070513C (en) 2010-05-05 2023-01-03 Boehringer Ingelheim International Gmbh A dpp-4 inhibitor for use in treatment of skin-alterations or necrosis
WO2012016419A1 (zh) 2010-08-06 2012-02-09 浙江贝达药业有限公司 Glp-1衍生物及其应用
MX377589B (es) 2010-12-16 2025-03-10 Novo Nordisk As Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
SG191252A1 (en) 2010-12-22 2013-07-31 Marcadia Biotech Inc Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN102718858B (zh) 2011-03-29 2014-07-02 天津药物研究院 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
WO2012136790A1 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
CN102229668A (zh) 2011-06-03 2011-11-02 浙江贝达药业有限公司 一种glp-1衍生物及其应用
US20140220134A1 (en) 2011-06-24 2014-08-07 Astrazeneca Pharamceuticals LP Method for treating diabetes with extended release formulation of glp-1 receptor agonists
LT2753312T (lt) 2011-09-08 2017-01-25 Mereo Biopharma 2 Limited Aromatazės inhibitoriaus panaudojimas hipogonadizmo ir susijusių ligų gydymui
JP6250034B2 (ja) * 2012-05-08 2017-12-20 ノヴォ ノルディスク アー／エス 二重アシル化されたｇｌｐ−１誘導体
NZ727849A (en) 2012-06-29 2018-06-29 Amarin Pharmaceuticals Ie Ltd Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
HRP20251088T1 (hr) 2012-07-01 2025-11-07 Novo Nordisk A/S Upotreba dugodjelujućih peptida glp‑1
JP6672140B2 (ja) * 2013-05-02 2020-03-25 ノヴォ ノルディスク アー／エス Ｇｌｐ−１化合物の経口投薬
KR102844773B1 (ko) 2015-12-23 2025-08-13 암젠 인크 위 억제 펩티드 수용체 (gipr)에 대한 결합 단백질을 glp-1 효능제와 조합하여 사용하여 대사 장애를 치료하거나 개선시키는 방법
JP2020529440A (ja) 2017-08-04 2020-10-08 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 糖尿病および関連する状態の処置におけるガボキサドールの使用
JP7148605B2 (ja) 2017-10-12 2022-10-05 ノヴォ ノルディスク アー／エス 医学療法におけるセマグルチド

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023238017A1 (en) * 2022-06-08 2023-12-14 Zydus Lifesciences Limited Reusable multi-dose, variable dose, single pen injector for type 2 diabetes and weight management

Also Published As

Publication number Publication date
ZA202503387B (en) 2025-09-25
IL322969A (en) 2025-10-01
CN120241968A (zh) 2025-07-04
ZA202503350B (en) 2025-09-25
MX2025002189A (es) 2025-04-02
JP7475398B2 (ja) 2024-04-26
CN119950682A (zh) 2025-05-09
US20240415935A1 (en) 2024-12-19
TW201914611A (zh) 2019-04-16
AU2018348929B2 (en) 2025-02-27
SG11202002841PA (en) 2020-04-29
US20200237876A1 (en) 2020-07-30
EP3694538A1 (en) 2020-08-19
MX2025002188A (es) 2025-04-02
IL273470A (en) 2020-05-31
AU2025203535A1 (en) 2025-06-05
CL2020000812A1 (es) 2020-08-14
US12295988B2 (en) 2025-05-13
US12029779B2 (en) 2024-07-09
KR20200069316A (ko) 2020-06-16
MX2020003049A (es) 2020-07-27
US12551536B2 (en) 2026-02-17
JP2020536854A (ja) 2020-12-17
MY204827A (en) 2024-09-18
CA3078652A1 (en) 2019-04-18
CN119838000A (zh) 2025-04-18
ZA202503388B (en) 2025-09-25
RU2020114960A (ru) 2021-10-28
MA50358A (fr) 2020-08-19
TWI842681B (zh) 2024-05-21
IL322968A (en) 2025-10-01
US20240316159A1 (en) 2024-09-26
JP7148605B2 (ja) 2022-10-05
WO2019072941A1 (en) 2019-04-18
US20250235511A1 (en) 2025-07-24
AU2018348929A1 (en) 2020-05-07
RU2020114960A3 (https=) 2022-02-11
PH12020550185A1 (en) 2021-03-01
JP2022132414A (ja) 2022-09-08
CN111212657A (zh) 2020-05-29

Similar Documents

Publication Publication Date Title
BR112020006246A2 (pt) Método para controle do peso de um sujeito em necessidade
Ishii et al. Liraglutide reduces visceral and intrahepatic fat without significant loss of muscle mass in obese patients with type 2 diabetes: a prospective case series
JP2020019790A (ja) プラダー・ウィリー症候群を治療する方法
CN117355297A (zh) 用于诱导褐色脂肪生成的方法和组合物
Gusti et al. Effects of oxandrolone on lean body mass (Lbm) in severe burn patients: a randomized, double blind, placebo-controlled trial
BRPI0712051A2 (pt) combinação de análogos de somatostatina com antagonista de receptor do hormÈnio de crescimento ou dopamina
US20240277745A1 (en) Pemafibrate and/or tofogliflozin for use in treating liver disease
US20180055848A1 (en) Combination of Albuterol and Caffeine as Synergistic Treatment for Obesity or Sarcopenia
CN110636847A (zh) 用于预防及治疗肌肉疾病的组合物
BR122025013280A2 (pt) Uso de semaglutida para fabricar uma solução injetável subcutânea para tratar diabetes tipo 2
Snehalatha et al. Metformin in prevention of type 2 diabetes
BR122024015868A2 (pt) Uso de semaglutida para preparação de uma composição farmacêutica para tratamento e/ou prevenção de obesidade e/ou de sobrepeso
BR122024015864A2 (pt) Uso de semaglutida para preparação de uma composição farmacêutica para controle de peso
CN101879151A (zh) 大黄素在制备p2x3介导神经病理痛/神经系统疾病药物中的应用
WO2021224338A1 (en) Treatment of hyperuricemia
KR102927165B1 (ko) 메트포르민을 포함하는 시상하부 염증 치료 또는 예방용 약학적 조성물
KR102246627B1 (ko) Ｈｍｂａ를 포함하는 비만 또는 당뇨의 예방 또는 치료용 조성물
RU2800651C2 (ru) Семаглутид в лекарственной терапии
US20260053769A1 (en) Uses of selective androgen receptor modulator (sarm) compounds for quality weight loss
US20250228804A1 (en) Uses of selective androgen receptor modulator (sarm) compounds for quality weight loss
CN121969358A (zh) 选择性雄激素受体调节剂（sarm）化合物在长期体重管理中的用途
Sanchetee et al. Diabetes and Cancer
Kimonis et al. Glycemic Impact of Long-Term Use of Diazoxide Choline Controlled-Release Tablets in Patients with Prader-Willi syndrome or with Very High Triglycerides
De Ng et al. Pharmacological management update: clinical significance of anamorelin clinical trials for the treatment of cancer cachexia in advanced cancer patients

Legal Events

Date Code Title Description
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122024015864-7 PROTOCOLO 870240065542 EM 02/08/2024 11:45.O PEDIDO FOI DIVIDIDO NO BR122024015868-0 PROTOCOLO 870240065553 EM 02/08/2024 12:07.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 7.1 NA RPI NO 2824 DE 18/02/2025 POR TER SIDO INDEVIDA.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122025013280-2 PROTOCOLO 870250053867 EM 26/06/2025 15:59.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O E 11 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]